Lawrence Recht

Clinical Focus

• Cancer > Neuro Oncology
• Neurology

Professional Education

• Memorial Sloan-Kettering Cancer Center (1984) NY USA
• Board Certification: Neurology, American Board of Psychiatry and Neurology (1983)
• New York Presbyterian Hospital (1982) NY
• University of Minnesota School of Medicine (1979) MN
• University of Minnesota School of Medicine (1978) MN
• Columbia Presbyterian Medical Center (1977) NY
• M.D., Columbia College of P&S Medicine (1977)

Postdoctoral Advisees

• Furong Yu

Research Interests

Our laboratory focuses on two interrelated projects: (1) assessment of glioma development within the framework of the multistage model of carcinogenesis through utilization of the rodent model of ENU neurocarcinogenesis; and (2) assessment of stem cell specification and pluripotency using an embryonic stem cell model system in which neural differentiation is induced.

Clinical Trials

• BIBW 2992 With or Without Daily Temozolomide For Recurrent Malignant Glioma Recruiting
• Phase 2 of Azixa™ (MPC-6827) for Glioblastoma Multiforme in First or Second Relapse Recruiting
• An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed
• Phase II/III Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) No longer recruiting
• XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed
• XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema No longer recruiting
• Assessing the suitability of an imaging probe for use in clinical cell and gene therapy trials in cancer and rheumatoid arthritis No longer recruiting
• Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma Completed

Publications

• A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection. Jang T,  Sathy B, Hsu YH, Merchant M, Recht B, Chang C, Recht L.  J Neurosurg.  2008; 108 (4): 782-90
• Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. Bredel M,  Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI.  J Clin Oncol.  2006; 24 (2): 274-87
• Optimizing therapy for patients with brain metastases. Kuo T,  Recht L.  Semin Oncol.  2006; 33 (3): 299-306
• Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. Jang T,  Savarese T, Low HP, Kim S, Vogel H, Lapointe D, Duong T, Litofsky NS, Weimann JM, Ross AH, Recht L.  Am J Pathol.  2006; 168 (5): 1676-85
• Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. Bredel M,  Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR, Sikic BI.  J Mol Diagn.  2005; 7 (2): 171-82
• High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Bredel M,  Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.  Cancer Res.  2005; 65 (10): 4088-96
• Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Bredel M,  Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.  Cancer Res.  2005; 65 (19): 8679-89
• Treatment of neoplastic meningitis: what is the standard of care? Recht L,  Phuphanich S.  Expert Rev Neurother.  2004; 4 (4 Suppl): S11-7
• Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Colocci N,  Glantz M, Recht L.  Semin Neurol.  2004; 24 (4): 395-404